Skip to search formSkip to main contentSkip to account menu

GDC-0032

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Taselisib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis byPIK3CAandESR1mutation status from circulating…
Background: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in hormone receptor (HR)-positive breast… 
2017
2017
Abstract 146: The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models
Activating mutations in PIK3CA are commonly found in a wide variety of human cancers, and the dysregulation of the… 
2016
2016
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or…
TPS617Background: PIK3CA mutations are one of the most frequent genomic alterations in BC, being present in ~40% of ER-positive… 
2016
2016
Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC-MS/MS.
2016
2016
Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or…
Background:PIK3CA mutations are one of the most frequent genomic alterations in breast cancer (BC), being present in ∼40% of… 
2015
2015
Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer
Background: Taselisib (GDC-0032) is a next-generation PI3K inhibitor with increased anti-tumor activity against PIK3CA mutant (MT… 
2013
2013
Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Modifications of the phosphoinositide-3 kinase (PI3K… 
2013
2013
Abstract P4-15-02: The PI3K inhibitor GDC-0032 enhances the efficacy of standard of care therapeutics in PI3K alpha mutant breast cancer models
The phosphoinositide 3-kinases (PI3Ks) are lipid kinases that activate the PI3K signaling pathway and play an essential role in… 
2013
2013
Abstract B218: Drug-drug interaction assessment of GDC-0032, a beta-sparing inhibitor of phosphoinositide 3-kinase (PI3K), using midazolam, a sensitive CYP3A4 substrate.
Background: GDC-0032 is an orally-bioavailable, potent, and selective inhibitor of Class IA PI3K alpha, delta, gamma, and p110… 
2013
2013
Evaluation of tolerability and anti-tumor activity of GDC-0032, a PI3K inhibitor with enhanced activity against PIK3CA mutant tumors, administered-to patients with advanced solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)